Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 7625940, 5 pages
http://dx.doi.org/10.1155/2016/7625940
Case Report

Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases

1Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA
2Department of Pathology, Stony Brook University Hospital, Stony Brook, NY, USA
3Division of Hematology and Oncology, Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA
4Division of Gastroenterology, Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA

Received 4 June 2016; Accepted 8 September 2016

Academic Editor: Peter F. Lenehan

Copyright © 2016 Brandon Yim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Sipe, M. D. Benson, J. N. Buxbaum et al., “Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis,” Amyloid, vol. 19, no. 4, pp. 167–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Merlini and V. Bellotti, “Molecular mechanisms of amyloidosis,” The New England Journal of Medicine, vol. 349, no. 6, pp. 583–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Cohen and R. L. Comenzo, “Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy,” ASH Education Book, vol. 2010, no. 1, pp. 287–294, 2010. View at Publisher · View at Google Scholar
  4. M. A. Park, P. S. Mueller, R. A. Kyle, D. R. Larson, M. F. Plevak, and M. A. Gertz, “Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients,” Medicine, vol. 82, no. 5, pp. 291–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Systemic Light Chain Amyloidosis Version 1.2016, National Comprehensive Cancer Network, 2016.
  6. G. Palladini and G. Merlini, “What is new in diagnosis and management of light chain amyloidosis?” Blood, vol. 128, no. 2, pp. 159–168, 2016. View at Publisher · View at Google Scholar
  7. M. A. Gertz, “Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment,” American Journal of Hematology, vol. 91, no. 9, pp. 947–956, 2016. View at Google Scholar
  8. T. Bochtler, U. Hegenbart, C. Kunz et al., “Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone,” Amyloid, vol. 21, no. 1, pp. 9–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Bochtler, U. Hegenbart, C. Kunz et al., “Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens,” Journal of Clinical Oncology, vol. 33, no. 12, pp. 1371–1378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Palladini, S. Sachchithanantham, P. Milani et al., “A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis,” Blood, vol. 126, no. 5, pp. 612–615, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Senkus and J. Jassem, “Cardiovascular effects of systemic cancer treatment,” Cancer Treatment Reviews, vol. 37, no. 4, pp. 300–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. F. Reis-Mendes, E. Sousa, M. D. L. Bastos, and V. M. Costa, “The role of the metabolism of anticancer drugs in their induced-cardiotoxicity,” Current Drug Metabolism, vol. 17, no. 1, pp. 75–90, 2016. View at Google Scholar · View at Scopus
  13. S. Diwadkar, A. A. Patel, and M. G. Fradley, “Bortezomib-induced complete heart block and myocardial scar: the potential role of cardiac biomarkers in monitoring cardiotoxicity,” Case Reports in Cardiology, vol. 2016, Article ID 3456287, 5 pages, 2016. View at Publisher · View at Google Scholar
  14. M. Skinner, V. Sanchorawala, D. C. Seldin et al., “High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study,” Annals of Internal Medicine, vol. 140, no. 2, pp. 85–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Madan, S. K. Kumar, A. Dispenzieri et al., “High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement,” Blood, vol. 119, no. 5, pp. 1117–1122, 2012. View at Publisher · View at Google Scholar · View at Scopus